Compare SPT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPT | EVO |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.6M | 895.8M |
| IPO Year | 2019 | N/A |
| Metric | SPT | EVO |
|---|---|---|
| Price | $5.54 | $2.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $12.38 | $7.00 |
| AVG Volume (30 Days) | ★ 1.7M | 110.9K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $457,547,000.00 | N/A |
| Revenue This Year | $9.03 | N/A |
| Revenue Next Year | $8.83 | $7.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.72 | N/A |
| 52 Week Low | $5.39 | $2.31 |
| 52 Week High | $24.74 | $4.80 |
| Indicator | SPT | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 34.76 | 32.84 |
| Support Level | N/A | $2.31 |
| Resistance Level | $7.39 | $3.75 |
| Average True Range (ATR) | 0.31 | 0.08 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 15.75 | 21.76 |
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.